Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole

被引:24
作者
Andersson, T [1 ]
Bredberg, E [1 ]
Lagerström, PO [1 ]
Naesdal, J [1 ]
Wilson, I [1 ]
机构
[1] Astra Hassle AB, Clin Res & Dev, S-43183 Molndal, Sweden
关键词
NSAID; diclofenac; naproxen; piroxican; omeprazole; interaction;
D O I
10.1007/s002280050482
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To study, in three separate investigations, the potential interaction between omeprazole and three different non-steroidal anti-inflammatory drugs (NSAIDs; diclofenac, naproxen and piroxicam) in healthy male and female subjects. Methods: Each investigation was an open, randomized, three-way cross-over study, in which the subjects were given omeprazole 20 mg once daily for 1 week, the NSAID in therapeutic daily doses (diclofenac 50 mg bid, naproxen 250 mg bid, or piroxicam 10 mg om), or a combination of omeprazole and each NSAID. The plasma concentrations of the NSAID as well as of omeprazole were determined on the last day of each investigation period. Results: None of the NSAIDs studied had any effect on the plasma concentration Versus time curve (AUC) of omeprazole. It was also demonstrated that omeprazole 20 mg daily had no significant influence on the pharmacokinetics of the NSAIDs. The AUC ratio, (NSAID + omeprazole):NSAID alone, was 1.11, 0.99, and 0.99 for diclofenac, naproxen, and piroxicam, respectively. Conclusion: Diclofenac, naproxen, and piroxicam can be administered together with omeprazole 20 mg daily without need for dosage alteration. There was no significant change in the bioavailability of theses NSAIDs during omeprazole therapy in this study.
引用
收藏
页码:399 / 404
页数:6
相关论文
共 39 条
[1]   A STUDY OF THE INTERACTION BETWEEN OMEPRAZOLE AND PHENYTOIN IN EPILEPTIC PATIENTS [J].
ANDERSSON, T ;
LAGERSTROM, PO ;
UNGE, P .
THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :329-333
[2]   IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING SECONDARY OMEPRAZOLE METABOLISM [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (06) :597-604
[3]   IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING OMEPRAZOLE METABOLISM [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
TASSANEEYAKUL, W ;
TASSANEEYAKUL, W ;
MEYER, UA ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (06) :521-530
[4]   SLOW OMEPRAZOLE METABOLIZERS ARE ALSO POOR S-MEPHENYTOIN HYDROXYLATORS [J].
ANDERSSON, T ;
REGARDH, CG ;
DAHLPUUSTINEN, ML ;
BERTILSSON, L .
THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :415-416
[5]  
Andersson T, 1991, THESIS U GOTEBORG SW
[6]   ABSENCE OF AN INHIBITORY EFFECT OF OMEPRAZOLE AND NIZATIDINE ON PHENYTOIN DISPOSITION, A MARKER OF CYP2C ACTIVITY [J].
BACHMANN, KA ;
SULLIVAN, TJ ;
JAUREGUI, L ;
REESE, JH ;
MILLER, K ;
LEVINE, L .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (04) :380-382
[7]  
BROOKS PM, 1991, NEW ENGL J MED, V324, P1716
[8]  
CHIBA K, 1993, J PHARMACOL EXP THER, V266, P52
[9]   RELATIONSHIP BETWEEN PHENYTOIN AND TOLBUTAMIDE HYDROXYLATIONS IN HUMAN LIVER-MICROSOMES [J].
DOECKE, CJ ;
VERONESE, ME ;
POND, SM ;
MINERS, JO ;
BIRKETT, DJ ;
SANSOM, LN ;
MCMANUS, ME .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (02) :125-130
[10]  
EKENVED G, 1975, ACTA PHARM SUEC, V12, P323